parecoxib has been researched along with Benign Neoplasms, Brain in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Darabi, A; Eberstål, S; Fritzell, S; Sandén, E; Siesjö, P; Visse, E | 1 |
| Badn, W; Darabi, A; Eberstål, S; Esbjörnsson, M; Fritzell, S; Siesjö, P; Visse, E | 1 |
2 other study(ies) available for parecoxib and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Female; Flow Cytometry; Glioma; Granulocyte-Macrophage Colony-Stimulating Factor; Immunoenzyme Techniques; Immunotherapy; Intramolecular Oxidoreductases; Isoxazoles; Mice; Mice, Inbred C57BL; Prostaglandin-E Synthases; Sulfonamides; Tumor Cells, Cultured | 2014 |
Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Flow Cytometry; Glioblastoma; Immunohistochemistry; Immunotherapy, Adoptive; Interferon-gamma; Isoxazoles; Male; Neoplasms, Experimental; Rats; Rats, Inbred F344 | 2012 |